Shaalan Beg MD MBA FASCO

🧵 During today’s National Cancer Advisory Board (#NCAB) meeting, I shared updates on where NCI stands—and where we’re headed. I see a research enterprise that is steady, focused, and ready to accelerate progress against cancer. Here are a few highlights:

No role for debulking of multiorgan metastatic colorectal cancer! Highlights the role of a multidisciplinary evaluation upfront - it’s all or none. @BiachiTiago @DanielAnayaMD @ColonCancerFdn @GaertnerWB @ChildersBg @ShaalanBeg @laleh_melstrom @VautheyMD @CathyEngMD

Intriguing data from MDACC- neoadjuvant CAPTEM in locally advanced or metastatic PanNETs. ORR was only 6.4%, tumor vessel involvement was modified from >180° to ≤180° in only 16.2%. No statistically significant shift in TVI with treatment. Four patients had a change from an unresectable primary tumor to an anatomically resectable tumor following CAPTEM. A little surprised by these data knowing CAPTEM works fairly well in the metastatic disease setting. 40% ORR. It has worked well in a handful of cases where I have used it for with neoadjuvant intent. Unsure if MGMT testing would help select candidates in this space. pmc.ncbi.nlm.nih.gov/articles/PMC12…

Someone suggested I make a table summarizing the video. Here it is!

Many ppl are operated on who would otherwise do just as well w SBRT. This study is a great example..much better data than ncdb-esque analysis addressing such qs. I hope we see similar data for pancreas cancer soon.

Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials - European Journal of Cancer ejcancer.com/article/S0959-…

American healthcare is administratively complex, legally fragmented, and deeply shaped by your zip code. None of that is accidental. All of it is fixable with good policy design. Grateful to present our work on cancer care, policy, and law today at the @hopkinskimmel Grand Rounds, the place that trained me. @ONealCancerUAB @HopkinsMedicine

Adaptive radiotherapy involves modifying treatment plans to account for changes in anatomical geometry that are not adequately mitigated with changes in alignment. Online adaptive radiotherapy capitalizes on advances in image guidance, real-time tumor tracking, and the enhanced speed of multiple steps in radiotherapy planning and delivery workflows (seen in image). Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: nejm.org/doi/full/10.10…

Next-generation KRAS G12C inhibitor olomorasib shows promising pan-tumor activity in a first-in-human study. ORR ~37% in non-CRC tumors with durable response. Activity even observed after prior KRAS G12C inhibitors. KRAS targeting keeps evolving. nature.com/articles/s4146…

Please give our full episode a listen! youtu.be/W9A5np8R5tM?si…

🏈 We all saw the MCED Super Bowl ad. The NHS–Galleri 🩸💉 trial press release is out: The Primary endpoint was NOT met. A big blow to the field? 🥊 Are we only scratching the surface of early detection biomarkers? #OnlyOncologistsInTheBuilding break it down for you!

Have you ever wondered whether you need to hold systemic during RT due to concern for additive toxicity? See this 10 min video. Categorized by systemic type (cytoxic chemo, IO, TKI, BRAF, etc) & RT regimen (SBRT/conventional/palliative) Slides🧵& full video below. 1/8

Emerging landscape of KRAS inhibitors in cancer treatment @Cancer_Cell doi.org/10.1016/j.ccel… 👏great review 👉Tsunami of new drugs and oppertunities @myESMO @ASCO

@sethmhardy @LancetGastroHep @ShrutiPatelMD @cancerassassin1 @NiuSanford @VivekSubbiah @marklewismd @mcuban @TimothyJBrownMD @UGrewalMD Huh? Pilots are doing scopes now? I'm kidding.. 😂 In seriousness, I don't think it's old news... I think it's very relevant to medicine today.,. different specialties will shake up differently as AI makes it way into workflow

@ShaalanBeg @LancetGastroHep @ShrutiPatelMD @cancerassassin1 @NiuSanford @VivekSubbiah @marklewismd @mcuban @TimothyJBrownMD @UGrewalMD Pilots have already been there and done that. Old news.

Can artificial intelligence cause doctors to lose their skills? The answer according to this study in @LancetGastroHep is "YES!". So that begs the question, "Does that even matter? " #onlyoncologistsinthebuilding break it down for you. thelancet.com/journals/langa…

After exposure to artificial intelligence, this study revealed, that gastroenterologists' polyp detection rates went down. Link to our full episode 👇🏻 👇🏻 youtu.be/1qGBrq4ZR9g?si…

@NiuSanford @ASCO @montypal @umangtalking @DVAraujoMD @JamesBatesMD You guys got t-shirts?!?! @AshleySumrallMD

Final session in Alexandria, VA with this great @ASCO LDP class. The year went by fast! Thank you to our coaches & staff 🙏.

🔵🔵 CRC rates ⬆️ in young 👫 ❓Reasons unknown 🔵See our recent work w cBioportal on a unique mutation in EOCRC👇🏽👇🏽👇🏽 Mutations in Exon 29 of Ring Finger Protein 213 Are Associated with Early-Onset Colorectal Cancer ⁦@NYULH_DeptofMed⁩ link.springer.com/article/10.100…

Best evidence yet that GLP-1 drugs reduce the risk of substance abuse, from >600,00 US Veterans across alcohol, nicotine, opioid, cocaine, cannabis @bmj_latest @zalaly @Miao_Cai_SLU bmj.com/content/392/bm…

9️⃣ years later, the story of dual immune checkpoint blockade in metastatic RCC is still being written. The final "very" long-term follow-up of CheckMate-214 confirms what many hoped in 2018: durable survival, deep responses, and a subset of patients who may experience long-term disease control with nivolumab + ipilimumab. A short 🧵 on what 9+ years of follow-up teach us about immunotherapy in kidney cancer since Bernard Escudier @myESMO 2018 plenary presentation sciencedirect.com/science/articl…